Researchers track blistering skin disease to pave way for better treatments
NCT ID NCT02753777
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how severe autoimmune blistering diseases like pemphigus and bullous pemphigoid are and how they affect quality of life. Researchers will enroll 150 adults to test disease severity scales and quality-of-life questionnaires. The goal is to create better tools for future clinical trials, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Apr 2016
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients over the age of 18 who have been diagnosed with pemphigus vulgaris, pemphigus foliaceus or bullous pemphigoid.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Gender/Age: Males or females above 18 years old * Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid * Subjects able to give informed consent Exclusion Criteria: * Patients who are under age 18 years. * Patients without pemphigus or pemphigoid diseases * Penn employees * Penn students * Cognitively impaired persons
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bullous pemphigoid are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Hospital of the University of Pennsylvania, Department of Dermatology
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
University of Pennsylvania, Department of Dermatology
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted biologic outperform standard care for a rare blistering disease?
- Engineered immune cells take aim at blistering skin disease
- Can an extra shot boost COVID protection in autoimmune patients?
- Laser and steroid mouthwash aim to tame painful mouth sores in autoimmune disease
- Study reveals bone risks from common skin treatment
- Scientists probe hidden clot risks in autoimmune skin disorders